Sobi Global

OUR SCIENCE | R&D Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE Q4 and FY 2025 report Sobi published its Q4 and FY 2025 report on 5 February 2026.ReportPresentationWebcastInvitationAide memoire Financial reports MEDIA | PRESS RELEASES Press releases 5 February, 2026 08:00 Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress 3 February, 2026 09:15 Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026 Learn more

2 members

Contact info

Link

sobi.com

Members

Carla Bell

•

3rd+

Journalist and Editorial Consultant / Director, MAYDAY:Black

Roberta Pantani

•

3rd+

A regulatory affairs professional with 15+ years of global regulatory experience. Effective key contributor to the preparation and submission of multiple NDA and MAA. Provided regulatory leadership to project teams in all stages of clinical development. Strategic roles in the preparations and conduct of several Regulatory Agency meetings. Experience in the therapeutic areas of oncology, anti-infective, cardio-renal and ophthalmology. Strong interpersonal and communication skills.